The company focuses on developing mass-market affordable residential housing projects and managing a portfolio of real estate assets and investments in associate companies.
The company lacks a competitive advantage, evidenced by zero revenue from core operations over multiple years and a reliance on 'other income' from partnership interests. Low returns on capital and a lack of project execution suggest no pricing power or cost advantage.
Capital is primarily deployed as interest-free unsecured loans to struggling associate companies and subsidiaries, many of which are being liquidated or struck off. This has resulted in significant impairment losses rather than shareholder value creation.
The company's collapse was the inevitable conclusion of a business that functioned more as a non-performing lender to related parties than a real estate developer. By 2029, the 'material uncertainty' regarding its going concern status became a certainty as the remaining interest-free loans to associate companies were fully written off following their liquidation. With zero operational revenue and no core business to fall back on, the company was unable to service its own obligations, leading to a total evaporation of equity value as the shell was finally abandoned by its promoters.
RichFakir rates Ladam Affordable Housing Ltd's business quality as poor — 16/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Ladam Affordable Housing Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Ladam Affordable Housing Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Ladam Affordable Housing Ltd's fair value is about ₹0 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →